Comparing Marpai (NASDAQ:MRAI) and Global Cord Blood (NYSE:CORBF)

Global Cord Blood (NYSE:CORBF) and Marpai (NASDAQ:MRAI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Global Cord Blood and Marpai’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$196.12 million	0.77	$79.04 million	N/A	N/A
Marpai	$37.16 million	0.69	-$28.75 million	($4.41)	-0.56

Global Cord Blood has higher revenue and earnings than Marpai.

Institutional & Insider Ownership

49.8% of Marpai shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by insiders. Comparatively, 61.3% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Global Cord Blood and Marpai’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Marpai	-77.38%	N/A	-75.05%

Analyst Recommendations

This is a breakdown of current recommendations for Global Cord Blood and Marpai, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0	0	0	0	N/A
Marpai	0	0	1	0	3.00

Marpai has a consensus price target of $6.00, suggesting a potential upside of 141.94%. Given Marpai’s higher probable upside, analysts plainly believe Marpai is more favorable than Global Cord Blood.

Volatility and Risk

Global Cord Blood has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, Marpai has a beta of 5.41, meaning that its stock price is 441% more volatile than the S&P 500.

About Global Cord Blood

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

About Marpai

Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, bill review and cost containment services. It also develops artificial intelligence and healthcare technology. Marpai, Inc. was incorporated in 2021 and is headquartered in New York, New York.